Intracerebral interleukin 12 induces glioma rejection in the brain predominantly by CD8+ T cells and independently of interferon-γ

Journal of Neuropathology and Experimental Neurology

Volumn 68, Issue 5, 2009, Pages 525-534

  Vetter, Marcus ^a   Hofer, Markus J ^a   Roth, Evelyn ^b   Pircher, Hans Peter ^b   Pagenstecher, Axel ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Glioma; Immune therapy; Interleukin 12

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; ANTINEOPLASTIC AGENT; CD45 ANTIGEN; CYTOKINE; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BRAIN; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TUMOR REJECTION; WILD TYPE; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CANCER TRANSPLANTATION; DISEASE MODEL; DRUG EFFECT; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; TUMOR CELL CULTURE; UPREGULATION;

ANIMALS; ANTIGENS, CD45; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOMA; IMMUNOTHERAPY; INTERFERON-GAMMA; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 70149112087     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181a2afa0     Document Type: Article

References (44)

1. Louis DN, Ohgaki H, Wiestler OD, et al. WHO Classification of Tumours of the Central Nervous System. Lyon, France: IARC, 2007
2. Kortmann RD, Jeremic B, Weller M, et al. Radiochemotherapy of malignant glioma in adults. Clinical experiences. Strahlenther Onkol 2003;179:219-232
3. Linos E, Raine T, Alonso A, et al. Atopy and risk of brain tumors: A meta-analysis. J Natl Cancer Inst 2007;99:1544-1550
4. Grauer OM, Sutmuller RP, van Maren W, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysateYpulsed dendritic cells in a murine glioma model. Int J Cancer 2008;122:1794-1802
5. Tran TT, Uhl M, Ma JY, et al. Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. Neuro Oncol 2007; 9:259-270
6. Mariani CL, Kouri JG, Streit WJ. Rejection of RG-2 gliomas is mediated by microglia and T lymphocytes. J Neurooncol 2006;79:243-253
7. Aulwurm S, Wischhusen J, Friese M, et al. Immune stimulatory effects of CD70 override CD70-mediated immune cell apoptosis in rodent glioma models and confer long-lasting antiglioma immunity in vivo. Int J Cancer 2006;118:1728-1735
8. Wood GW, Turner T, Wang YY, et al. Immune rejection of intracerebral gliomas using lymphocytes from glioma-bearing rats. J Immunother 1999;22:497-505
9. Fathallah-Shaykh HM, Gao W, Cho M, et al. Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity. Int J Cancer 1998;75:266-276
10. Ehtesham M, Kabos P, Kabosova A, et al. The use of interleukin 12Ysecreting neural stem cells for the treatment of intracranial glioma. Cancer Res 2002;62:5657-63.
11. Roy EJ, Gawlick U, Orr BA, et al. IL-12 treatment of endogenously arising murine brain tumors. J Immunol 2000;165:7293-7299
12. Yu WG, Yamamoto N, Takenaka H, et al. Molecular mechanisms underlying IFN-gammaYmediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996;8:855-865
13. Kito T, Kuroda E, Yokota A, et al. Cytotoxicity in glioma cells due to interleukin-12 and interleukin-18Ystimulated macrophages mediated by interferon-gammaYregulated nitric oxide. J Neurosurg 2003;98: 385-392
14. Badn W, Visse E, Darabi A, et al. Postimmunization with IFNgammaYsecreting glioma cells combined with the inducible nitric oxide synthase inhibitor mercaptoethylguanidine prolongs survival of rats with intracerebral tumors. J Immunol 2007;179:4231-4238
15. Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, et al. Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol 2000;164:217-222
16. Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 geneVA phase I/II clinical protocol. J Neurooncol 2003; 64:147-154
17. Kikuchi T, Akasaki Y, Abe T, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004;27:452-459
18. Pagenstecher A, Lassmann S, Carson MJ, et al. Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the CNS and modulates experimental allergic encephalomyelitis. J Immunol 2000;164:4481-4492
19. Hofer M, Hausmann J, Staeheli P, et al. Cerebral expression of interleukin-12 induces neurological disease via differential pathways and recruits antigen-specific T cells in virus-infected mice. Am J Pathol 2004;165:949-958
20. Cobbold SP, Jayasuriya A, Nash A, et al. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature 1984;312: 548-551
21. Van den Steen PE, Van Aelst I, Starckx S, et al. Matrix metalloproteinases, tissue inhibitors of MMPs and TACE in experimental cerebral malaria. Lab Invest 2006;86:873-888
22. Campbell IL, Eddleston M, Kemper P, et al. Activation of cerebral cytokine gene expression and its correlation with onset of reactive astrocyte and acute-phase response gene expression in scrapie. J Virol 1994;68:2383-2387
23. Hobbs MV, Weigle WO, Noonan DJ, et al. Patterns of cytokine gene expression by CD4+ T cells from young and old mice. J Immunol 1993; 150:3602-3614
24. Dudov KP, Perry RP. The gene family encoding the mouse ribosomal protein L32 contains a uniquely expressed intron-containing gene and an unmutated processed gene. Cell 1984;37:457-464
25. Freude S, Hausmann J, Hofer M, et al. Borna disease virus accelerates inflammation and disease associated with transgenic expression of interleukin-12 in the central nervous system. J Virol 2002;76: 12223-12232
26. Sonabend AM, Velicu S, Ulasov IV, et al. A safety and efficacy study of local delivery of interleukin-12 transgene by PPC polymer in a model of experimental glioma. Anticancer Drugs 2008;19:133-142
27. Lee YS, Kim JH, Choi KJ, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res 2006;12:5859-5868
28. Yamanaka R, Zullo SA, Tanaka R,et al. Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12. Neurosurg Focus 2000;9:e7
29. Kim CH, Hong MJ, Park SD, et al. Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12. Cancer Immunol Immunother 2006;55:1309-1319
30. Yamanaka R, Zullo SA, Ramsey J, et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virusYmediated interleukin-12. J Neurosurg 2002;97:611-618
31. Joki T, Kikuchi T, Akasaki Y, et al. Induction of effective antitumor immunity in a mouse brain tumor model using B7-1 (CD80) and intercellular adhesive molecule 1 (ICAM-1; CD54) transfection and recombinant interleukin 12. Int J Cancer 1999;82:714-720
32. Szatmari T, Lumniczky K, Desaknai S, et al. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006;97:546-553
33. Hatterer E, Davoust N, Didier-Bazes M, et al. How to drain without lymphatics? Dendritic cells migrate from the cerebrospinal fluid to the B cell follicles of cervical lymph nodes. Blood 2006;107:806-812
34. Vega EA, Graner MW, Sampson JH. Combating immunosuppression in glioma. Future Oncol 2008;4:433-442
35. Roth P, Mittelbronn M, Wick W, et al. Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res 2007;67:3540-3544
36. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis. Cancer Res 2003;63:7462-7467
37. Takeda K, Hayakawa Y, Atsuta M, et al. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12. Int Immunol 2000;12:909-914
38. Kodama T, Takeda K, Shimozato O, et al. Perforin-dependent NK cell cytotoxicity is sufficient for anti-metastatic effect of IL-12. Eur J Immunol 1999;29:1390-1396
39. Smyth MJ, Taniguchi M, Street SE. The anti-tumor activity of IL-12: Mechanisms of innate immunity that are model and dose dependent. J Immunol 2000;165:2665-2670
40. Smyth MJ, Thia KY, Street SE, et al. Differential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med 2000;191:661-668
41. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008;27:5932-5943
42. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+ regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006;105:430-437
43. El Andaloussi A, Lesniak MS. CD4+ CD25+ FoxP3+ T cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol 2007;83:145-152
44. El Andaloussi A, Lesniak MS. An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme. Neuro Oncol 2006;8:234-43